+ All Categories
Home > Documents > OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry...

OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry...

Date post: 01-Nov-2020
Category:
Upload: others
View: 2 times
Download: 0 times
Share this document with a friend
8
ONCOLOGY | CA 20 YEARS www.chi.org
Transcript
Page 1: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

OncOlOgy | cA

20YEARS

www.chi.org

Page 2: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

2 | www.chi.org

MEET STEvE BArrAGEr: HOW BIOSCIENCE HELPS PATIENTS LIvE LONGEr AND HEALTHIEr

neW MoleCUlAr enTiTieS (nMes) APProVeD For The TreATMenT oF CAnCer bY YeAr:

number of nMEs approved nationally:

The CAliForniA bioSCienCe SeCTor develops cutting-edge cancer treatments that help patients live longer, healthier lives. The pace of innovation has quickened in recent years, bringing us closer to previously unimagined treatments. california companies have hundreds of oncology products in the development pipeline. continued federal and private investment in research will be critical to the ongoing development of lifesaving therapies and the creation of high-paying, biomedical jobs.

Recent data demonstrate that from 1990 to 2008 the overall death rate from cancer has decreased by 18% which translates to approximately

1,024,000 saved livesduring that time period.

4 42

7

12

2008 2009 2010 2011 2012

It started in 2005 with severe back pain and loss of

energy and appetite. Every few months, I complained

to my doctor of pain. In January 2007, with more pain

than ever, I went to an orthopedic specialist and had

x-rays taken of my spine. The specialist referred me to a

general practitioner, who ordered new tests but decided

just two days later, “we are wasting time.” That’s when an

oncologist told me “I think you have cancer.” By the end

of that day, February 16, 2007, I was diagnosed with

advanced multiple myeloma, a rare blood cancer—facing imminent kidney failure

and collapsing vertebrae.

For three years I took the few approved drugs available for my cancer. They fi rst

controlled the disease, but caused side effects that hospitalized me for weeks.

The next treatment was better, but lost its effectiveness, as is common in the

type of cancer I have. We were desperate when my oncologist recommended a

clinical trial at the University of california, San Francisco.

I was fortunate. Three months on the trial, I had minimal side effects and an

amazing response: my tests came back normal. I can’t kayak anymore, but I am

enjoying a relatively normal and productive life: I have started a digital publishing

company, and I think I might get to see my grandchildren grow up.

My multiple myeloma will certainly adapt to the current treatment, but I hope that

there will be a new drug available when I need it. I urge policymakers to invest in

biomedical research, because patients like me depend on it.

Steve and Sandraline Barrager

Page 3: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

www.chi.org | 3

ADvANCING CANCEr THErAPY AND TrEATMENT The pace of innovation in oncology is accelerating. nationally, 29 nMEs have been approved since 2008. Healthier behaviors, better care, and innovative treatments are helping people live longer. According to the most recent data available from the national cancer Institute (ncI), “overall cancer death rates continued to decline in the United States among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites.”

Source: National Cancer Institute, 1/7/13

DeSPiTe The FAST PACe oF innoVATion, CAnCer reMAinS The nATion’S SeConD leADing CAUSe oF DeATh. It takes extensive investment, experimentation and time to develop new treatments and secure government approval. Each experiment or study helps lay the groundwork for advances to come. Signifi cant challenges still remain for certain recalcitrant cancers (e.g., pancreatic, lung, esophageal, brain, multiple myeloma, and liver), which are the deadliest cancers. The promise of innova-tions like individualized oncological treatments can be fulfi lled with continued investment in a robust product pipeline.

IN CALIfOrNIA, 278 cancer TreaTmenTs WErE IN DEvELOPMENT IN 2012 ALONE, uP frOM 253 IN 2011.

CALIfOrNIA HAS MOrE THAN 1,400 producTs IN THE PIPELINE, rEPrESENTING

21% of THe ToTal biomedical pipeline in

the U.S

278253

2012

2011

ncI has projected that the number of cancer survivors will rise from 13.7 million today to over

18 million in 2020

iMProVeMenT in 5-YeAr relATiVe SUrViVAl rATeS FroM 1975-2008:

20081975

All sites

Brain

Breast

liver

Prostate

Myeloma

colorectal

lung

49%

3%

75%

68%100%

25%

51%

12%17%

43%

65%

22%

68%

90%

16%

35%

Page 4: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

4 | www.chi.org

Source: 2013 California Biomedical Industry Report (CHI, BayBio and PwC)

ToTal producT sales were $35 billion in 2011.

ToTal revenue for the california biomedical industry was $69.2 billion.

Source: 2012 Battelle/BIO State Bioscience Industry Development Report

california’s bioscience innovators employ almost 153,000 people, paying more than $15.5 billion in annual wages and accounting for $20 billion in exports to markets around the world.

$101,658

$82,697

From 2001-2010, the bioscience industry grew by 6.4%, adding more than 96,000 high-paying jobs.

By comparison, total employment for all private sector industries in the U.S. fell by 2.9 percent, representing a loss of more than 3 million jobs.

On average, bioscience jobs paid $82,697 in 2010, $36,000 more than the national average for highly skilled private sector jobs.

The U.S. biopharmaceutical sector employs more than 650,000 workers, supports a total of 4 million jobs across the country, and contributes more than

$917 billion in economic output on an annual basis.

On average, california’s annual salaries in the bio-medical industry were $18,961 higher than the national average for highly skilled employees in 2012.

BIOSCIENCE AND THE ECONOMY: IMPACT AT A GLANCEcalifornia’s bioscience companies and research institutions are major employers that create life-saving therapies, provide highly valued jobs, and grow the economy.

THE SECTOr’S IMPACT ON THE california economyMore than 2,300 biomedical companies and public and private research institutions are located in california.

BIOSCIENCE COMPANIES AND rESEArCH INSTITuTIONS CONTrIBuTE BILLIONS TO THE naTional economy. From 2001 to 2010, the U.S. bioscience industry added high-paying jobs, despite net losses in both private sector industry employment and other leading knowledge-based industries.

Page 5: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

www.chi.org | 5

FDA

nIHA

cA

DEM

Ic lABORATORIES

PRIVATE SEcT

OR

THE niH, academic laboraTories, THE PriVATe

SeCTor AnD THE fda All EXIST On A cOnTInUUM, AnD EAcH PlAyS A cRITIcAl ROlE. THE nIH FUnDS RESEARcH TO UnlOcK THE MySTERIES OF HUMAn BIOlOgy AnD THE

cAUSES OF DISEASE.

Source: 2012 Battelle/BIO State Bioscience Industry Development Report

Source, PhRMA 2013 Industry Profi le

In 2012 alone, industry funded $48.5 billion in new bioscience R&D projects, the largest R&D investment relative to size, and more than any other industry.

THE CYCLE Of INNOvATIONThe economic competitiveness of the United States depends largely on our ability to maintain and grow our position in science, technology, innovation, and research. yet, we face critical challenges: increased competition from other countries, the lack of adequate funding for early stage product development, and the recurring threat of reduced nIH funding for biomedical research.

Some might consider our current environment and this list of challenges insurmountable, but I see a “context for change” and view these circumstances as opportunities. It’s time we reinvigorate the “quantum leap” culture that has become synonymous with biomedical innovation.

Tony Coles, M.D., Chairman & CEO, Onyx Pharmaceuticals

california’s bioscience investors rely on both venture capital

investment and federal research funds from the nIH and the

nSF. In 2012, combined funding totaled $10.7 billion.

nationally, the nIH invests more than $30.9 billion

annually in medical research.

In 2012 alone, industry funded $48.5 billion in new bioscience R&D projects, the largest R&D investment relative to market

size, and more than any other industry.

More than 80 percent of the nIH’s funding is awarded through almost 50,000

competitive grants to more than 300,000 researchers at more than 2,500 universities,

medical schools, and other research institutions in every state and around the world.

Page 6: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

6 | www.chi.org

COLLABOrATION AND INNOvATION: BIOSCIENCE INNOvATOrS ACrOSS CALIfOrNIAMuch of the work that leads from basic research to clinical therapies is collaborative, taking place at leading companies and research centers such as the University of california, San Diego (UcSD) Moores cancer center.

San Diego is a powerhouse for cancer research, home to UcSD Moores cancer center – the region’s only ncI-designated comprehensive cancer center – and two ncI-designated centers for basic research: the Salk Institute cancer center and the cancer center at Sanford-Burnham Medical Research Institute. These singular enterprises have now formed a novel collaboration – the San Diego national cancer Institute cancer centers council, or c3 – to leverage their distinct and combined resources and talents. This new partnership will allow San Diego’s cancer researchers to accelerate the understanding of, and innovative treatments for, cancer.

BIOSCIENCE ACrOSS CALIfOrNIAcollaborations like c3 support networks of companies and institutions that contribute to the economy and provide jobs to a large number of californians.

The private sector is helping translate basic research into the robust product pipelines that lead to marketable treatments. california has more than 1,400 products in the pipeline, representing 21 percent of the total biomedical pipeline in the U.S. In california, 278 cancer treatments were in development last year alone, up from 253 in 2011. Source: CHI/Bay BIO/PwC

17% 15% 15%6% 5%

San Francisco Bay Area

47,019 jobs

San Diego county

25,883 jobs

los Angeles county

23,054 jobs

Orange county

23,004 jobs

Ventura & Santa Barbara

counties9,047 jobs

Riverside & San Bernadino

counties7,354 jobs

Sacramento county

1,979 jobs

31%

1%

Page 7: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

www.chi.org | 7

rECENT DEvELOPMENTS IN CANCEr THErAPYRecent advances in molecular biology have transformed our ability to understand cancer genomics, advance more precise therapeutic strategies, and develop better screening technologies. In just the past few years, ncI-supported science has delivered an impressive amount of genetic information about several kinds of cancers, and many new observations about the genesis of cancer cells, their development and behavior, and their microenvironment. government-supported research like this provides an important foundation for developing new clinical therapies.

PERSOnAlIZIng VAccInES: A new vaccine for glioblastoma multiforme (gBM), a cancer of the nervous system, helps patients live longer than with other therapies. The vaccine is custom-made for each patient using her or his own cancer tissue.

Researchers from the University of california, San Francisco collaborated with northwestern University researchers to create the vaccine, which is injected into a patient’s skin and engages the immune system to fi ght the cancer. Trials showed a 25% improvement in survival of six months or more.

BREAKIng THROUgH cAncER’S DEFEnSES: Stanford researchers have discovered that nearly every kind of cancer cell has a large amount of cD47 on the cell surface. This protein signal protects the cancer against attack by the body’s immune system. Stanford investigators have discovered that if they block the cD47 “don’t-eat-me” signal through the use of anti-cD47 antibodies, macrophages will consume and destroy cancer cells. Deadly human cancers have been diminished or eliminated in animal models through the use of anti-cD47 antibodies. (http://stemcell.stanford.edu/cD47/)

USIng cOlD VIRUSES TO FIgHT cAncER: Findings by a team of scientists at the Salk Institute for Biological Studies suggest that cold viruses might be a valuable ally in the fi ght against cancer. Adenovirus, one kind of cold virus, has developed tools allowing it to hijack cell processes involved in growth, replication and cancer suppression. The fi ndings suggest a new avenue for developing cancer therapies by mimicking the strategies employed by the viruses. (http://www.salk.edu/news/pressrelease_details.php?-press_id=583)

DEVElOPIng STEM cEll THERAPIES: city of Hope, an ncI-designated comprehensive cancer center, is conducting a fi rst-in-human investi-gational study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive types of brain tumors. neural stem cells can help deliver therapies to tumor sites, which may help meet two major chal-lenges facing current gene therapy strategies: effective delivery and distribution of a therapeutic agent through-out tumor sites.(http://www.cityofhope.org/patient_care/treat-ments/Brain-tumors/Pages/default.aspx)

Page 8: OncOlOgy | cA - CLSA · 2017. 3. 13. · Source: 2012 Battelle/BIO State Bioscience Industry Development Report Source, PhRMA 2013 Industry Profi le In 2012 alone, industry funded

abouT THe california HealTHcare insTiTuTe:

The california Healthcare Institute (cHI) was founded in

1993 as an independent 501(c)(6) organization devoted to

researching and advocating policy to forward the interests

of california’s biomedical community.

cHI has built a membership of more than 275 leading

biomedical companies, academic and research

institutions, and companies involved in

supporting the biomedical community.

www.cHi.org

20YEARS


Recommended